Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company has received an acceptance notice approved and issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small-molecule drug SAL0139 tablets (project code: SAL0139) has been accepted for review. According to the announcement, SAL0139 is a small-molecule drug with independent intellectual property rights owned by the company. The application submitted by the company this time is for a clinical trial of SAL0139 for the treatment of hyperlipidemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments